Patents Issued in January 30, 2018
-
Patent number: 9879064Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.Type: GrantFiled: June 23, 2015Date of Patent: January 30, 2018Assignee: Horizon Orphan LLCInventors: Todd C. Zankel, Christopher M. Starr
-
Patent number: 9879065Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.Type: GrantFiled: September 13, 2013Date of Patent: January 30, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
-
Patent number: 9879066Abstract: The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.Type: GrantFiled: July 21, 2016Date of Patent: January 30, 2018Assignee: Genentech, Inc.Inventors: Ning Chai, Jacqueline McBride, Lee Swem
-
Patent number: 9879067Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: February 11, 2016Date of Patent: January 30, 2018Assignee: MedImmune, LLCInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 9879068Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.Type: GrantFiled: June 21, 2013Date of Patent: January 30, 2018Assignees: California Institute of Technology, The Rockefeller UniversityInventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
-
Patent number: 9879069Abstract: There is disclosed compositions and methods relating to or derived from anti-OprF and anti-OprI antibodies. More specifically, there is disclosed fully human antibodies that bind OprF and OprI, OprF and OprI-antibody binding fragments and derivatives of such antibodies, and OprF and OprI-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having Pseudomonas aeruginosa infections. There is disclosed a method for treating or preventing Pseudomonas aeruginosa infections, wherein the disease is selected from the group consisting of burns, surgical site infections, diabetic foot ulcers, infected wounds, and cystic fibrosis.Type: GrantFiled: August 28, 2015Date of Patent: January 30, 2018Assignee: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Gunnar F. Kaufmann
-
Patent number: 9879070Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: GrantFiled: November 6, 2013Date of Patent: January 30, 2018Assignee: MedImmune, LLCInventors: Brett Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
-
Patent number: 9879071Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: GrantFiled: September 5, 2012Date of Patent: January 30, 2018Assignee: Prothena Biosciences LimitedInventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Patent number: 9879072Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.Type: GrantFiled: October 27, 2011Date of Patent: January 30, 2018Assignee: AMGEN INC.Inventors: William Gleason Richards, Hsieng Sen Lu, Hua Zhu Ke, Chaoyang Li, Frederick W. Jacobsen
-
Patent number: 9879073Abstract: The present invention relates to the field of biochemistry and pharmaceutical technologies. The present invention provides nanobodies that bind to human pulmonary surfactant protein A (SP-A) as well as the preparing methods and use of the same. The nanobody comprise an amino acid sequence having the formula of Q(x)2LVESGG(x)2V(x)2G(x)SL(x)LS(x)24E(x)n2 KG(x)4S(x)n3T(x)2Y(x)C(x)n4S(x)n5V(x)n6R; wherein x is amino acid; n2˜n6 are positive integers; 1?n2?21; 1?n3?19; 1?n4?50; 1?n5?22; 1?n6?8. The present invention take fresh frozen sections of lung as antigen, gene sequences with high affinity with hSP-A were obtained by constructing an SP-A antibody library and affinity selection, and nanobodies with high affinity and small molecular weight were obtained by induced expression of the gene sequences through a prokaryotic expression vector. Immunohistochemistry and in vivo imaging in nude mice showed the nanobodies have high specificity for targeting lung tissue.Type: GrantFiled: April 8, 2015Date of Patent: January 30, 2018Assignee: SHANGHAI PULMONARY HOSPITALInventors: Huiping Li, Xian He, Shanmei Wang
-
Patent number: 9879074Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.Type: GrantFiled: May 29, 2015Date of Patent: January 30, 2018Assignee: ALDERBIO HOLDINGS LLCInventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 9879075Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.Type: GrantFiled: February 6, 2014Date of Patent: January 30, 2018Assignee: Yokohama City University and Chiome Bioscience Inc.Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
-
Patent number: 9879076Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.Type: GrantFiled: March 13, 2014Date of Patent: January 30, 2018Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Sarit Samira, Nurit Rachamim, Michael Tal, Ronald Ellis, Idan Rakover, Rom E. Eliaz, Beka Solomon, Timothy David Jones, Francis Joseph Carr, Polina Rabinovich-Toidman, Meital Sooliman
-
Patent number: 9879077Abstract: The present invention relates to antigen-binding fragment (Fab) and a Fab-effector fusion protein or (poly)peptide comprising thereof. The Fab of the present invention specifically binds to serum albumin and thereby has extended in vivo half-life. The Fab of the present invention is characterized by not having cysteine residues that are responsible for the interchain disulfide bond in CH1 domain and C?L domain as well. The Fab-effector fusion protein or (poly)peptide of the present invention can be produced in periplasm of E. coli with high yield, and has increased in vivo half-life. Further, the present invention provides E. coli strain which produces various kinds of Fab-effector fusion proteins or (poly)peptides, and a pharmaceutical composition comprising the fab-effector fusion proteins or (poly)peptides.Type: GrantFiled: February 29, 2016Date of Patent: January 30, 2018Assignee: AprilBio Co., Ltd.Inventor: Sanghoon Cha
-
Patent number: 9879078Abstract: A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.Type: GrantFiled: April 7, 2016Date of Patent: January 30, 2018Assignee: President and Fellows of Harvard CollegeInventors: Gokhan S. Hotamisligil, Haiming Cao
-
Patent number: 9879079Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: May 25, 2016Date of Patent: January 30, 2018Assignee: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 9879080Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: July 2, 2016Date of Patent: January 30, 2018Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORKInventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Patent number: 9879081Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.Type: GrantFiled: June 25, 2014Date of Patent: January 30, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Hye Young Suh, Jae Il Lee, Su-Jeong Hwang
-
Patent number: 9879082Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.Type: GrantFiled: January 27, 2015Date of Patent: January 30, 2018Assignee: NOVO NORDISK A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Rozana Sten, Lene Hjorth Alifrangis, Rune Viig Overgaard
-
Patent number: 9879083Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.Type: GrantFiled: December 19, 2013Date of Patent: January 30, 2018Assignee: AVEO Pharmaceuticals, Inc.Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 9879084Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: January 9, 2017Date of Patent: January 30, 2018Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
-
Patent number: 9879085Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: April 17, 2017Date of Patent: January 30, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
-
Patent number: 9879086Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.Type: GrantFiled: September 17, 2015Date of Patent: January 30, 2018Assignee: ZYMEWORKS INC.Inventors: Geoffrey C. Winters, James R. Rich, Graham Albert Edwin Garnett, Alexander Laurence Mandel, Tom Han Hsiao Hsieh, Elyse Marie Josée Bourque, Stuart Daniel Barnscher
-
Patent number: 9879087Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: GrantFiled: January 4, 2016Date of Patent: January 30, 2018Assignee: SIAMAB THERAPEUTICS, INC.Inventors: Julie DeSander, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
-
Patent number: 9879088Abstract: The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.Type: GrantFiled: April 26, 2017Date of Patent: January 30, 2018Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi, Diane Rossi
-
Patent number: 9879089Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.Type: GrantFiled: May 1, 2015Date of Patent: January 30, 2018Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
-
Patent number: 9879090Abstract: The present invention relates to isolated VHHs directed against human Glycophorin A. The present invention also relates to fusion proteins comprising the VHH according to the invention that is fused to at least one heterologous polypeptide and immunoconjugates comprising the VHH according to the invention that is conjugated to at least one chemical compound and their use in therapeutic or diagnostic methods.Type: GrantFiled: March 4, 2014Date of Patent: January 30, 2018Assignees: INSERM (Institut National De La SantéEt De La Recherche Médicale, Imoversité Paris Diderot—Paris 7, Universite Des Antilles Et De La Guyane, Institut National De La Transfusion Sanguine (INTS)Inventors: Olivier Bertrand, Ibrahim Habib, Dorota Smolarek
-
Patent number: 9879091Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.Type: GrantFiled: August 7, 2014Date of Patent: January 30, 2018Assignee: ASTUTE MEDICAL, INC.Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
-
Patent number: 9879092Abstract: Anti-RhoB antibodies, compositions comprising the same, and methods for the treatment of autoimmune and inflammatory diseases using the anti-RhoB antibodies are disclosed.Type: GrantFiled: August 9, 2012Date of Patent: January 30, 2018Assignee: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Patent number: 9879093Abstract: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.Type: GrantFiled: December 20, 2012Date of Patent: January 30, 2018Assignees: ADAERATA, LIMITED PARTNERSHP, NATIONAL RESEARCH COUNCIL OF CANADAInventors: Nabil G. Seidah, Jianbing Zhang
-
Patent number: 9879094Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.Type: GrantFiled: August 11, 2016Date of Patent: January 30, 2018Assignee: Genentech, Inc.Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
-
Patent number: 9879095Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: February 21, 2013Date of Patent: January 30, 2018Assignee: HOFFMAN-LA ROCHE INC.Inventors: Ulrich Brinkmann, Alexander Haas, Silke Metz, Juergen Michael Schanzer
-
Patent number: 9879096Abstract: The present invention provides a process for the preparation of sugammadex sodium involving the step of: reacting 6-perdeoxy-6-per-halo-gamma-cyclodextrin with 3-mercapto propionic acid in the presence of alkali metal alkoxide in an organic solvents. The invention also provides a process for purifying the sugammadex or its pharmaceutically acceptable salts using water and organic solvents.Type: GrantFiled: April 8, 2013Date of Patent: January 30, 2018Assignee: NEULAND LABORATORIES LIMITEDInventors: Ponnaiah Ravi, Praveenkumar Neela, Batthini Guruswamy, Sribhashyam Ravikanth, Uppala Manikya Rao
-
Patent number: 9879097Abstract: When manufacturing a sugar chain compound having an activating group, there was a problem with the ammonium carbonate method that is the conventional technology that during the process of introducing an amino group at the reducing terminal of the sugar chain, the unit sugar located at the reducing terminal of the sugar chain is subjected to ring-opening, thus causing a mixture of ? and ? anomers to be produced.Type: GrantFiled: April 17, 2014Date of Patent: January 30, 2018Assignee: Glytech, Inc.Inventor: Takefumi Murase
-
Patent number: 9879098Abstract: In the high pressure polymerization of ethylene homopolymers or copolymers, conditions in the high pressure recycle system may lead to the build-up of low molecular weight oligomers and waxes. Sequentially draining knock-out pots, located downstream of a high pressure separator, at regular intervals can reduce the build-up of low molecular weight oligomers and waxes during the high pressure polymerization of alpha olefins.Type: GrantFiled: May 19, 2015Date of Patent: January 30, 2018Assignee: NOVA Chemicals (International) S.A.Inventors: James A. Auger, Craig Allan Hulet, Ross Donald Moreton, Benjamin Milton Shaw, Amanda Dolores Murphy
-
Patent number: 9879099Abstract: A polyethylene composition made from or containing a polyethylene, having the following features: 1) a density from about 0.930 to about 0.945 g/cm3, determined according to ISO 1183 at 23° C.; 2) a ratio of MIF/MIP from about 30 to about 55; 3) a MIF from about 3 to about 25 g/10 min.; 4) a Mz equal to or greater than about 1,500,000 g/mol; and 5) a long-chain branching index, LCBI, equal to or lower than about 0.55, wherein the LCBI is the ratio of the measured mean-square radius of gyration Rg, measured by GPC-MALLS, to the mean-square radius of gyration for a linear PE having about the same molecular weight of 1,000,000 g/mol.Type: GrantFiled: October 27, 2015Date of Patent: January 30, 2018Assignee: Basell Polyolefine GmbHInventors: Gerd Mannebach, Bernd Lothar Marczinke, Gerhardus Meier, Ulf Schuller, Iakovos Vittorias, Harilaos Mavridis
-
Patent number: 9879100Abstract: The present invention relates to a synergistic dual olefin copolymerization catalyst system comprising a solid support material having, on its surface, two or more catalytic metal complexes wherein the two or more catalytic metal complexes comprise at least one first transition metal complex and a second transition metal complex different from the first transition metal complex; use of such a system as a catalyst; a process for producing a polymer of an olefin utilizing the catalyst system.Type: GrantFiled: May 13, 2015Date of Patent: January 30, 2018Assignee: SCG Chemicals Co., Ltd.Inventors: Dermot O'Hare, Jean-Charles Buffet, Zoe Turner
-
Patent number: 9879101Abstract: A polymer having a long chain branching content peaking at greater than about 20 long chain branches per million carbon atoms, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 8 long chain branches per million carbon atoms, a polydispersity index of greater than about 20 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution. A polymer having a long chain branching content peaking at greater than about 1 long chain branches per chain, and a polydispersity index of greater than about 10 wherein the long chain branching decreases to approximately zero at the higher molecular weight portion of the molecular weight distribution.Type: GrantFiled: February 6, 2017Date of Patent: January 30, 2018Assignee: Chevron Phillips Chemical Company, LPInventors: Youlu Yu, Eric D. Schwerdtfeger, Max P. McDaniel, Alan L. Solenberger, Kathy S. Clear
-
Patent number: 9879102Abstract: A chain transfer agent composition comprises at least one branched C10 mercaptan selected from 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, or combinations thereof. The chain transfer agent composition can be a component of an emulsion polymerization mixture and can be used in a process for emulsion polymerization for the production of polymers, for example, via free-radical polymerization.Type: GrantFiled: March 20, 2017Date of Patent: January 30, 2018Assignee: Chevron Phillips Chemical Company LPInventors: Jason L. Kreider, Michael S. Matson
-
Patent number: 9879103Abstract: A lactide-functionalized polymer is synthesized by polymerizing a monomer capable of undergoing radical polymerization (e.g., styrenic, vinylic, acrylic, etc.) using a brominated lactide initiator via atom transfer radical polymerization (ATRP). In some embodiments of the present invention, the brominated lactide initiator is 3-bromo-3,6-dimethyl-1,4-dioxane-2,5-dione prepared by reacting lactide with N-bromosuccinimide in the presence of benzoyl peroxide.Type: GrantFiled: August 22, 2015Date of Patent: January 30, 2018Assignee: International Business Machines CorporationInventors: Dylan J. Boday, Timothy C. Mauldin
-
Patent number: 9879104Abstract: This invention relates to a process to using an aminopyridinate scandium or yttrium metal (typically scandium) catalyst compound to produce ethylene conjugated diene copolymers, preferably ethylene isoprene copolymers having: 1) from 75 to 90 mol % ethylene; 2) from 10 to 25 mol % isoprene; 3) a Tg of 0° C. or less; 4) 1,4 isomer present at 60 wt % or less; 5) 3,4 and 1,2 present at 40% or more; 6) Mn of 250,000 g/mol or less; and 7) optionally, a Tm of 100° C. or less.Type: GrantFiled: March 29, 2016Date of Patent: January 30, 2018Assignee: ExxonMobil Chemical Patents Inc.Inventors: John F. Walzer, Jr., Anna A. Michels, John R. Hagadorn, Sarah J. Mattler, Carlos R. Lopez-Barron, Anthony J. Dias
-
Patent number: 9879105Abstract: The instant invention provides a polyolefin composition, a catalyst composition, and a method of producing the same. The method for polymerizing one or more polyolefins according to the present invention comprises the steps of: (1) selecting a first olefin monomer and optionally one or more alpha-olefin comonomers; (2) selecting one or more catalyst systems comprising one or more procatalysts comprising a first metal selected from the group consisting of Ti, V, Hf, Zr, and combinations or mixture two or more thereof, one or more cocatalysts comprising Al, and one or more self-limiting agents (SLA) selected from the group consisting of polyether, polyester, and combinations or mixtures thereof; wherein the ratio of said SLA to said first metal (SLA:first metal) is from 0.Type: GrantFiled: October 30, 2014Date of Patent: January 30, 2018Inventors: Linfeng Chen, Stephanie M. Whited, Robert J. Jorgensen
-
Patent number: 9879106Abstract: Catalyst systems and methods for making and using the same are described. A method includes selecting a catalyst blend using a blend polydispersity index (bPDI) map. The polydispersity map is generated by generating a number of polymers for at least two catalysts. Each polymer is generated at a different hydrogen to ethylene ratio. At least one catalyst generates a higher molecular weight polymer and another catalyst generates a lower molecular weight polymer. A molecular weight for each polymer is measured. The relationship between the molecular weight of the polymers generated by each of the catalysts and the ratio of hydrogen to ethylene is determined. A family of bPDI curves for polymers that would be made using a number of ratios of a blend of the at least two catalysts for each of a number of ratios of hydrogen to ethylene.Type: GrantFiled: February 10, 2015Date of Patent: January 30, 2018Assignee: Univation Technologies, LLCInventors: Francis C. Rix, Ching-Tai Lue, Timothy M. Boller, Garth R. Giesbrecht, C. Jeff Harlan
-
Patent number: 9879107Abstract: A fluorinated copolymer excellent in adhesion and elongation deformation processability. This fluorinated copolymer has carbonyl groups, its melting point is from 120 to 230° C., the ratio (X/W) of the melt tension X (N) to the load W (N) at the time of measuring the melt tension X, is from 0.5×10?4 to 2.0×10?4, it contains units derived from the following monomers (a), (b), and (c), the molar ratio of the units derived from the monomer (a) to the units derived from the monomer (b) is from 30/70 to 70/30, and the total content of the units derived from the monomer (a) and the units derived from the monomer (b) is from 80 to 99.995 mol % based on the total of all units (a), (b) and (c): Monomer (a): tetrafluoroethylene; Monomer (b): ethylene; Monomer (c): a monomer having two or more polymerizable carbon-carbon double bonds.Type: GrantFiled: November 17, 2016Date of Patent: January 30, 2018Assignee: Asahi Glass Company, LimitedInventor: Tatsuya Terada
-
Patent number: 9879108Abstract: The composition includes (A) a pigment; and (B) a polymer having (b-1) a bulky amine moiety, (b-2) an acid group, and (b-3) a constituent unit derived from a macromonomer having a weight average molecular weight of 1000 to 50000, in which the bulky amine moiety (b-1) has a nitrogen atom, carbon atoms X1 bonded with the nitrogen atom, and carbon atoms Y1 bonded with the carbon atoms X1, and a total carbon number of the carbon atoms X1 and the carbon atoms Y1 is 7 or more.Type: GrantFiled: November 24, 2015Date of Patent: January 30, 2018Assignee: FUJIFILM CorporationInventors: Hiroaki Idei, Toshihito Kuge, Takashi Kawashima
-
Patent number: 9879109Abstract: Provided are rubber compositions for tires capable of providing tire components and pneumatic tires that have the same level of fuel efficiency and wet grip performance (particularly, wet grip performance) as those of tire components and pneumatic tires containing conventional synthetic rubber, while satisfying the requirements for a sound material-cycle society. The present invention relates to rubber compositions for tires containing a biomass-derived rubber polymerized from an aromatic vinyl compound and a diene, the biomass-derived rubber having a pMC (percent modern carbon) measured in accordance with ASTM D 6866-10 of 1% or higher.Type: GrantFiled: September 6, 2013Date of Patent: January 30, 2018Assignee: SUMITOMO RUBBER INDUSTRIES, LTD.Inventors: Ryoji Kojima, Yuka Yokoyama, Masafumi Yoshino
-
Patent number: 9879110Abstract: An AB-type block copolymer for use in printed circuit board (PCB) fabrication is provided having a structure represented by the following formula: wherein R1 is a silane pendant group that includes a silicon-containing moiety capable of bonding to a glass surface, and wherein R2 is a matrix-reactive pendant group that includes at least one moiety (e.g., a vinyl-, allyl-, amine-, amide- or epoxy-containing moiety) capable of reacting with a base polymer.Type: GrantFiled: November 21, 2014Date of Patent: January 30, 2018Assignee: International Business Machines CorporationInventors: Dylan J. Boday, Joseph Kuczynski, Timothy C. Mauldin
-
Patent number: 9879111Abstract: A resin mixture comprises a vinyl ester urethane resin as the base resin, wherein the vinyl ester urethane resin can be obtained by reacting a dianhydrohexitol compound with a diisocyanate to obtain a product and reacting the obtained product with a hydroxy substituted (meth)acrylate. The resin mixture can be used to produce a reactive resin mortar containing that resin mixture and inorganic aggregates, organic aggregates or a mixture thereof. The reactive resin mortar can be used for chemical fastening.Type: GrantFiled: April 24, 2015Date of Patent: January 30, 2018Assignee: HILTI AKTIENGESELLSCHAFTInventor: Michael Leitner
-
Patent number: 9879112Abstract: The present invention is related to novel preparative methods to a novel class of polymer network materials with a highly branched poly(glycidyl ether) (PGE) structure. Said polymer networks are prepared by a simple procedure involving ring-opening polymerisation and the method is applicable to a wide range of glycidyl ether containing monomers. The method comprises the step of copolymerising (A) at least one multi-topic glycidyl ether comprising at least three glycidyl ether groups with (B) at least one glycidyl ether component comprising at least one glycidyl ether group by ring opening polymerisation, wherein the multi-topic glycidyl ether (A) is glycerol glycidyl ether (GGE) having the Formula (I) and the glycidyl ether component (B) is selected from monoglycidyl ethers comprising one glycidyl ether group and diglycidyl ethers comprising two glycidyl ether groups.Type: GrantFiled: August 16, 2013Date of Patent: January 30, 2018Assignee: HELMHOLTZ-ZENTRUM GEESTHACHT ZENTRUM FUER MATERIAL—UND KUESTENFORSCHUNG GMBHInventors: Adam Sisson, Duygu Ekinci, Andreas Lendlein, Friedrich Alfons Jung, Nan Ma
-
Patent number: 9879113Abstract: The invention relates to compositions of ?,?-branched alkane carboxylic acids glycidyl esters with a define isomeric composition where the sum of the concentration of the blocked and of the highly branched isomers is at least 50%, preferably above 60% and most preferably above 75% on total composition.Type: GrantFiled: December 16, 2011Date of Patent: January 30, 2018Assignee: HEXION INC.Inventors: Christophe Steinbrecher, Cedric Le Fevere De Ten Hove, Robert Van't Sand, Denis Heymans, Aleksandra Joanna Kotlewska